Ignite Creation Date:
2025-12-24 @ 4:24 PM
Ignite Modification Date:
2025-12-28 @ 11:22 AM
Study NCT ID:
NCT07290166
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-18
First Post:
2025-12-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.
Sponsor:
Fudan University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-10-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-04-30
Completion Date Type:
ESTIMATED
First Submit Date:
2025-12-06
First Submit QC Date:
None
Study First Post Date:
2025-12-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-06
Last Update Post Date:
2025-12-18
Last Update Post Date Type:
ESTIMATED